Determination of hepatitis B virus (HBV) infections in key populations including prison inmates is crucial for formulating appropriate intervention approaches. However, in many low-income countries, such as Liberia, there is hardly any documentation on HBV prevalence among inmates. This study determined and evaluated the prevalence of HBV infections among incarcerated persons in the Monrovia Central Prison, Liberia. One hundred participants comprising 76 males and 24 females were studied. Participants’ demographic and potential risk factors information were obtained using a semi-structured questionnaire, and blood samples were collected for the analysis. Plasma was tested for five HBV serological markers, namely, HBsAg, HBsAb, HBeAg, HBeAb, and HBcAb. The seroreactivity of actively infected persons was confirmed by nucleic acid detection. Results of the serological assay showed that 34% of the participants had been exposed to the virus and 14% were actively infected. qPCR confirmed HBV DNA in seven actively infected samples. Statistical analysis indicated that a low level of education, a history of blood transfusion, and intravenous drug use, were significant predictors of active HBV infection and HBV exposure, respectively. These findings might make the testing and vaccination of convicts against HBV infection prior to their admission into prison facilities imperative.
1 January 2025 in International Journal of Microbiology
Two distinct types of human immunodeficiency virus (HIV), namely, HIV‐1 and HIV‐2 exist. HIV‐1 is responsible for the global pandemic and has an aggressive pathogenesis. On the contrary, HIV‐2 is not only less aggressive but also confined to West and Central African regions. Even after four decades of HIV research, a scalable cure or effective vaccine against HIV remains elusive. Consequently, the concept of a functional cure or vaccine, targeting to limit disease progression, allowing sufficient time for the immune response to clear the virus, has gained traction. Efforts to identify new therapeutic targets for development of a functional cure have focused on elite controllers, that is, individuals who naturally control HIV‐1 infection in the absence of antiretroviral therapy. However, little progress has been associated with these efforts perhaps due to the scarcity of elite controllers, who make up only 0.15% of HIV‐1 infected population globally. A distinct but largely unexplored subset of HIV patients comprise HIV‐1 and HIV‐2 dually infected individuals. This group of patients naturally presents with an attenuated disease progression phenotype akin to natural controllers. In this review, we discuss the attenuated disease progression phenomenon in dually infected individuals and offer potential explanations for this unanticipated observation. Additionally, we propose potential therapeutic and/or vaccine strategies that could leverage interactions of HIV‐1 and HIV‐2. Such strategies are likely to inform alternative therapeutics. A thorough understanding of the mechanism underlying the attenuated disease progression phenotype in HIV dually infected individuals is crucial for the design of a functional cure.
3 October 2022 in Contemporary Clinical Trials Communications
Clinical trials are an essential part of drug and vaccine development, as well as the development of new biomedical devices, and medical procedures. Successful enrolment of human volunteers is important to the success of any clinical trial anywhere around the globe. Enrolment is however affected by a number of factors including knowledge, attitudes, and perceptions (KAPs). We aimed to determine factors that are deemed important in improving participation in clinical trials within a Ghanaian community. This was a cross-sectional study that employed a structured questionnaire within the New Juaben South Municipal Assembly (NJSMA). Participants who were 18 years and above were included in this study. There were a total of 639 participants in this study. Participants’ demographics were collected and various questions were asked to assess their KAP towards participation in clinical trials. The mean age of participants was 29.03 ± 8.95 years, there were more males (51.96%) than females, 42.35% had tertiary education, 38.03% were artisans, 74.80% were Christians and 14.40% had previously participated in a clinical trial. Participants had average knowledge about clinical trials (CT) with a mean score of 7.56 ± 1.76 (63%). A significant association between knowledge levels and education was observed (χ2 = 100.3, p < 0.0001). Helping in advancing the medical knowledge was the key reason for participation in CT while mistrust of the medical system was the key setback in participation in CT. There was a generally positive attitude and a neutral perception towards participation in CTs. Groups intending to conduct CT should highlight the benefits of CT and address the perception of mistrust in the conduct of CTs in their education and sensitization programs before initiation of CTs in Ghana.
Background: Malaria remains a significant public health challenge in Sub‐Saharan Africa, including Ghana. Children and adults present with varying clinical and biochemical pictures in response to Plasmodium infection. Thus, the study aimed to explore the relationship between Plasmodium parasitemia and hematological, liver, and kidney function of children and adult participants, highlighting possible variations. Method: The cross‐sectional study was conducted in a public and a private health facility in the Eastern Region of Ghana from August 2023 to September 2023. Participants of the study comprised children under 5 years and adults 18 years and above. Structured questionnaires were used to gather participants' demographic information and medical history. Blood samples of participants were analyzed with standard microscopy technique for Plasmodium parasites. Hematological and biochemical parameters were also measured with fully automated hematology and chemistry analyzers, respectively. Data were analyzed using IBM SPSS Version 22. χ2 analysis was performed to determine if differences in the degree of Plasmodium parasitemia and some demographic characteristics were significant. Kruskal–Wallis and post‐hoc pairwise tests were used to determine differences in hematological and biochemical parameters across categories of Plasmodium parasitemia. Statistical significance was assumed at a p value < 0.05. Results: The study enrolled 362 participants, comprising of 71.8% (260/362) adults and 69.3% (251/362) females. No significant differences were observed among gender and age categories across parasitemia levels, although a higher proportion of children < 5 years (51.9%, 53/102) recorded high parasitemia. Adult participants with high parasitemia recorded significantly lower Hb, RBC, MCV, MCH and PLT but higher ALT and AST than those with lower and moderate parasitemia. However, there was no significant variations in urea and creatinine levels with regard to degree of parasitemia among the participants. Conclusion: High Plasmodium parasitemia was linked with significant hematological and hepatic alterations, with distinct variations between adults and children < 5. The alterations observed in patients with high parasitemia highlight the importance of frequent and routine monitoring of these patients to address potential dysfunction early to prevent severe complications.